UGT1A1 and pachyonychia congenita: Prior two studies did not discuss the subset of patients with UGT1A1-DV; patients with UGT1A1-DV were not prescribed in the PRODIGE 4 study [8], and the study of metastatic PC patients conducted in Japan excluded patients with UGT1A1-DV [9].